Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Shares Pass Above Two Hundred Day Moving Average – Should You Sell?

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) shares crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $45.77 and traded as high as $46.89. Global X Genomics & Biotechnology ETF shares last traded at $46.79, with a volume of 8,882 shares.

Global X Genomics & Biotechnology ETF Trading Up 1.1%

The company has a market capitalization of $52.40 million, a P/E ratio of -20.00 and a beta of 1.19. The firm’s 50 day moving average price is $44.96 and its two-hundred day moving average price is $45.77.

Institutional Trading of Global X Genomics & Biotechnology ETF

Several institutional investors and hedge funds have recently bought and sold shares of GNOM. Jane Street Group LLC grew its stake in shares of Global X Genomics & Biotechnology ETF by 7.7% in the first quarter. Jane Street Group LLC now owns 143,713 shares of the company’s stock valued at $1,143,000 after buying an additional 10,308 shares in the last quarter. Sei Investments Co. increased its stake in shares of Global X Genomics & Biotechnology ETF by 110.4% during the 2nd quarter. Sei Investments Co. now owns 23,073 shares of the company’s stock worth $194,000 after purchasing an additional 12,105 shares during the last quarter. Smartleaf Asset Management LLC increased its stake in shares of Global X Genomics & Biotechnology ETF by 30.9% during the 2nd quarter. Smartleaf Asset Management LLC now owns 19,548 shares of the company’s stock worth $164,000 after purchasing an additional 4,615 shares during the last quarter. IFP Advisors Inc increased its stake in shares of Global X Genomics & Biotechnology ETF by 20.8% during the 3rd quarter. IFP Advisors Inc now owns 2,835 shares of the company’s stock worth $110,000 after purchasing an additional 489 shares during the last quarter. Finally, U.S. Capital Wealth Advisors LLC acquired a new position in shares of Global X Genomics & Biotechnology ETF during the 4th quarter worth about $575,000. Institutional investors own 56.95% of the company’s stock.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.